Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
California regulators have revoked the license of a robotaxi service owned by General Motors after determining its driverless cars that recently began transporting passengers throughout San Francisco are a dangerous menace.
Walmart, the nation's largest private employer, is expanding nationwide its health care coverage next month for employees who want to enlist the services of a doula, a person trained to assist women during pregnancies.
A group of 33 states including California and New York are suing Meta Platforms Inc. for harming young people’s mental health and contributing the youth mental health crisis by knowingly designing features on Instagram and Facebook that addict children to its platforms.
In a courtroom showdown five years in the making, Donald Trump's fixer-turned-foe Michael Cohen testified Tuesday that he worked to boost the supposed value of the former president's assets to “whatever number Trump told us to."
